Literature DB >> 7484100

The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature.

D Soffer1, D Benharroch, V Berginer.   

Abstract

Cerebrotendinous xanthomatosis (CTX), a rare autosomal-recessive lipid storage disease, has been well characterized clinically and biochemically, and recently also from the molecular biological aspect. However, only a very few publications deal with its neuropathology, and views on its pathogenesis vary. Based on a recently examined case, we propose that central-peripheral distal axonopathy is the major pathogenetic mechanism of nervous system injury in CTX. The latter is characterized by white matter pathology, typically in form of long tract involvement with the more distal parts of the tract more severely affected. Most severely affected are the cerebellar white matter, the optic pathways and the long tracts of the brain stem and spinal cord, particularly the pyramidal tracts, although there is hardly a CNS region which does not display some form of pathology. Lesions are characterized by loss of myelinated fibers and accumulation of lipid products in form of foamy macrophages, clear oil-red-O-positive spaces and crystalline clefts, accompanied by gliosis, occasional axonal spheroids, and in the cerebellum--the most severely affected structure--also by multi-nucleated foreign body giant cells. Demyelination is not seen, and ultrastructurally myelin sheaths are normally structured. Signs of axonal degeneration are also present in the spinal roots. We hypothesize that the basic enzymatic defect in CTX leads to accumulation of metabolites in the brain which may be neurotoxic and may impair the metabolic apparatus of neurons with resultant axonopathy and subsequent nonspecific lipid deposition in the injured tracts.

Entities:  

Mesh:

Year:  1995        PMID: 7484100     DOI: 10.1007/bf00294324

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  28 in total

1.  [Cerebrotendinous xanthomatosis. Apropos of a case using magnetic resonance study of the brain and nerve biopsy].

Authors:  H Amiel; R Gherardi; H Y Kanaan; J Buisson; R Genthon; J Zinszner; C Giroux; P Delaporte; J Salama
Journal:  Ann Med Interne (Paris)       Date:  1989

Review 2.  Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature.

Authors:  M Kuriyama; J Fujiyama; H Yoshidome; S Takenaga; K Matsumuro; T Kasama; K Fukuda; T Kuramoto; T Hoshita; Y Seyama
Journal:  J Neurol Sci       Date:  1991-04       Impact factor: 3.181

3.  Cerebrotendinous xanthomatosis: in vivo labeling of cerebral sterols and sterol esters.

Authors:  D Gardner-Medwin; Y Kishimoto; B M Derby; H W Moser
Journal:  Trans Am Neurol Assoc       Date:  1971

4.  Subcellular distribution of cerebral cholestanol in cerebrotendinous xanthomatosis.

Authors:  W L Stahl; S M Sumi; P D Swanson
Journal:  J Neurochem       Date:  1971-03       Impact factor: 5.372

5.  Permanent axotomy, a model of axonal atrophy and secondary segmental demyelination and remyelination.

Authors:  P J Dyck; A C Lais; J L Karnes; M Sparks; H Hunder; P A Low; A J Windebank
Journal:  Ann Neurol       Date:  1981-06       Impact factor: 10.422

6.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis.

Authors:  J J Cali; C L Hsieh; U Francke; D W Russell
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

7.  Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients.

Authors:  Y Hokezu; M Kuriyama; R Kubota; M Nakagawa; J Fujiyama; M Osame
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

8.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

9.  Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands.

Authors:  R J Waterreus; B J Koopman; B G Wolthers; H J Oosterhuis
Journal:  Clin Neurol Neurosurg       Date:  1987       Impact factor: 1.876

10.  Peripheral neuropathy in cerebrotendinous xanthomatosis.

Authors:  D A Katz; L Scheinberg; D S Horoupian; G Salen
Journal:  Arch Neurol       Date:  1985-10
View more
  12 in total

1.  Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings.

Authors:  M T Dotti; A Rufa; A Federico
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

2.  Cerebrotendinous xanthomatosis: neuropathological findings.

Authors:  B Pilo de la Fuente; I Ruiz; A Lopez de Munain; A Jimenez-Escrig
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

3.  The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Antonio Federico; Nicola De Stefano; Marco Battaglini; Irene Grazzini; Paolo Galluzzi; Lucia Monti
Journal:  J Neurol       Date:  2017-03-21       Impact factor: 4.849

4.  Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations.

Authors:  Chiung-Chih Chang; Chun-Chung Lui; Jiun-Jie Wang; Shu-Hua Huang; Cheng-Hsien Lu; Ching Chen; Chih-Feng Chen; Min-Chien Tu; Chi-Wei Huang; Wen-Neng Chang
Journal:  BMC Neurol       Date:  2010-07-06       Impact factor: 2.474

Review 5.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 6.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

7.  Quantification of brain damage in cerebrotendinous xanthomatosis with magnetization transfer MR imaging.

Authors:  Matilde Inglese; Nicola De Stefano; Elisabetta Pagani; Maria T Dotti; Giancarlo Comi; Antonio Federico; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-03       Impact factor: 3.825

Review 8.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

Review 9.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

Review 10.  Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.

Authors:  Olivier Bonnot; Hans Hermann Klünemann; Frederic Sedel; Sylvie Tordjman; David Cohen; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.